Page last updated: 2024-12-07

leucine-beta-naphthylamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Leucine-beta-naphthylamide, also known as L-leucyl-beta-naphthylamide, is a synthetic compound used primarily as a substrate for the enzyme leucine aminopeptidase (LAP). LAP is a hydrolase enzyme that plays a role in protein breakdown. Leucine-beta-naphthylamide is hydrolyzed by LAP, releasing beta-naphthylamine, which can be detected spectrophotometrically. This property makes leucine-beta-naphthylamide a valuable tool for studying LAP activity in various research settings. It is used to measure LAP levels in biological samples, assess the effects of inhibitors on LAP activity, and investigate the role of LAP in different biological processes. Leucine-beta-naphthylamide is a key component in the development of LAP inhibitors, which may have therapeutic potential in conditions related to protein metabolism and cancer.'

leucine-beta-naphthylamide: aminopeptidase substrate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

L-leucine 2-naphthylamide : An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of L-leucine with the amino group of 2-naphthylamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID102475
CHEMBL ID22905
CHEBI ID90476
SCHEMBL ID1820784
MeSH IDM0119667

Synonyms (37)

Synonym
2-amino-4-methyl-n-(2-naphthyl)pentanamide
732-85-4
l-leucine beta-naphthylamide
chebi:90476 ,
CHEMBL22905
n-naphthalen-2-yl-l-leucinamide
(2s)-2-amino-4-methyl-n-naphthalen-2-ylpentanamide
pentanamide, 2-amino-4-methyl-n-2-naphthalenyl-, (s)-
n-l-leucyl-2-naphthylamine
einecs 211-990-0
leucine-2-naphthylamide
leucine-beta-naphthylamide
leu-nap
(s)-2-amino-4-methyl-n-2-naphthylvaleramide
(l)-leucine-beta-napthylamide
SCHEMBL1820784
l-leucine-2-naphthylamine hydrochloride (salt/mix)
n-(2-naphthyl)-l-leucinamide hydrochloride (salt/mix)
l-leucyl-.beta.-naphthylamide hydrochloride (salt/mix)
l-leucine .beta.-naphthylamide
l-leucine-2-naphthylamine
n-(2-naphthyl)-l-leucinamide
valeramide, 2-amino-4-methyl-n-2-naphthyl-, l-
l-leucyl-.beta.-naphthylamide
l-leucine .beta.-naphthylamide hydrochloride (salt/mix)
n-(beta-naphthyl)-l-leucinamide
l-leucine 2-naphthylamide
n-leucyl-2-aminonaphthalene
h-leu-bna
mfcd00055914
Q27162564
(s)-2-amino-4-methyl-n-(naphthalen-2-yl)pentanamide
pentanamide,2-amino-4-methyl-n-2-naphthalenyl-,(2s)-
(2s)-2-amino-4-methyl-n-(2-naphthalenyl)pentanamide
DTXSID20993920
EN300-26145228
(2s)-2-amino-4-methyl-n-(naphthalen-2-yl)pentanamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
chromogenic compoundColourless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into coloured compounds. They are used in biochemical assays and in diagnosis as indicators, particularly in the form of enzyme substrates.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
N-(2-naphthyl)carboxamideAny carboxamide resulting from the formal condensation of a carboxylic acid with 2-naphthylamine.
amino acid amideAn amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.
L-leucine derivativeA proteinogenic amino acid derivative resulting from reaction of L-leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-leucine by a heteroatom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID197603Lysozyme-conjugated prodrugs: in vitro stability at pH 51992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID197599Lysozyme-conjugated prodrugs: in vitro stability at pH 51992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID197595Lysozyme-conjugated prodrugs: in vitro stability at pH 51992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID197601Lysozyme-conjugated prodrugs: in vitro stability at pH 7.41992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID197597Lysozyme-conjugated prodrugs: in vitro stability at pH 7.41992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID197727Lysozyme-conjugated prodrugs: in vitro stability at pH 7.41992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (52.94)18.7374
1990's5 (29.41)18.2507
2000's1 (5.88)29.6817
2010's2 (11.76)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.66 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]